Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,001–7,100 of 15,747
Scola, L., Ferraro, D., Sanfilippo, G. L., Grazia, S. D., Lio, D., & Giammanco, G. (2023) · Vaccines · doi:10.3390/vaccines11020413 · Cited by 9
“The Pfizer-BioNTech vaccine BNT162b2, based on lipoic nanoparticles containing the mRNA for the spike (S) protein [1], will be introduced at the end of 2020.”
MethodZazzeron, L., Rosovsky, R. P. G., Bittner, E. A., & Chang, M. G. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000519 · Cited by 10
Safe reopening of university campuses is possible with COVID-19 vaccination
Junge, M., Li, S., Samaranayake, S., & Zalesak, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270106 · Cited by 11
Onoda, K., Sashida, R., Fujiwara, R., et al. (2022) · Journal of Neurosurgery Case Lessons · doi:10.3171/case22101 · Cited by 10
“These vaccines often use mRNA, such as those developed by Pfizer-BioNtech or Moderna.(1,2) They did not show serious adverse effects in ongoing phase III clinical trials,(1,2) and there was a high level of efficacy and safety across all populations although many side effects of neurological involvements have been show…”
BackgroundMethodInfluentialChen, Y., Lee, C.-Y., Cheng, H., Chen, C., Cheuh, Y.-N., Lee, C.-L., & Kuo, H.-W. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.10.013 · Cited by 11
Mattar, C. N. Z., Koh, W. L. C., Seow, Y., Hoon, S. S., Venkatesh, A., Dashraath, P., Lim, L. M., Ong, J., Lee, R. J. Y., Johana, N. B., et al. (2021) · medRxiv · doi:10.1101/2021.05.23.21257686 · Cited by 10
Morton, B., Jambo, K., Chikaonda, T., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17172.1 · Cited by 10
Coronavirus Disease-2019 and Implications on the Liver
Campbell, P. T., & Fix, O. K. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.003 · Cited by 10
“This contrasts with a 94%-95% reduction in SARS-CoV-2 infections after two doses of anmRNA vaccine in the general population.(65,66) The severity of liver disease is also associated with impaired response to vaccination.”
Beilhack, G. F., Monteforte, R., Frommlet, F., Gaggl, M., Straßl, R. P., & Vychytil, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780594 · Cited by 10
“A negative correlation between age and number of adverse events in response to mRNA vaccines has been reported previously (4, 42).”
BackgroundShould Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?
Lamptey, E. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0134 · Cited by 10
Tamura, T., Ninomiya, K., Kubo, T., Kuyama, S., Tachibana, S., Inoue, K., Chikamori, K., Kudo, K., Ochi, N., Harada, D., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14281 · Cited by 8
“As a local reaction, pain was observed in many patients, but redness and swelling were less, and local pain tended to be less than the data reported in the BNT162b2 phase 3 trial (Figures 2 and S2).(7) Although the frequency of fever after vaccination tends to be high, it is considered that the SARSCoV-2 mRNA vaccine…”
BackgroundMethodResultInfluentialEvaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman PrimatesPreprint
Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M. J., Foulds, K. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.21.445189 · Cited by 14
Rivera‐Izquierdo, M., Soler‐Iborte, E., de Rojas, J. P., Pegalajar‐García, M. D., Villalba, A. G., Ruíz‐Villaverde, R., & Valero-Ubierna, M. D. C. (2021) · Vaccines · doi:10.3390/vaccines10010015 · Cited by 12
“Although the efficacy and safety of this vaccine have been widely studied [7,8], several articles have reported adverse reactions to this vaccine in the general population [9] and in healthcare workers [3–5].”
BackgroundA prospective cohort study of preconception COVID-19 vaccination and miscarriage
Yland, J. J., Wesselink, A. K., Regan, A. K., Hatch, E. E., Rothman, K. J., Savitz, D. A., Wang, T. R., Huybrechts, K. F., Hernández–Díaz, S., Eisenberg, M. L., et al. (2023) · Human Reproduction · doi:10.1093/humrep/dead211 · Cited by 10
Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data
Almohaya, A. M., Alsubie, H., Alqarni, B. A., Alzayad, B., Alghar, A., Alshahrani, K. A., & Barry, M. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.001 · Cited by 10
“BNT162B2, a lipid nanoparticle that encapsulates nucleoside modified mRNA that encodes the SARS CoV 2 full length spike (S) protein, demonstrated 95% efficacy in preventing COVID-19 disease, seven days following a two-dose regimen [3].”
BackgroundWillingness to pay for booster dose of COVID-19 vaccine among healthcare workers in Taizhou,China
Pan, S.-J., Yang, Y., Zhang, M., & Tung, T. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2063629 · Cited by 11
Kikuchi-Fujimoto disease following SARS-CoV-2 vaccination
Ikeda, K., Kakehi, E., Adachi, S., & Kotani, K. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-250601 · Cited by 12
Optimism and caution for an inactivated COVID-19 vaccine
Rostad, C. A., & Anderson, E. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30988-9 · Cited by 11
Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure
Campbell, G. R., & Spector, S. A. (2021) · Cells · doi:10.3390/cells10071798 · Cited by 10
Humphrey, L., Thommes, E. W., Fields, R., Coudeville, L., Hakim, N., Chit, A., Wu, J., & Cojocaru, M. G. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.06.008 · Cited by 10
Wang, Y.-C., Chen, T., Teng, C. J., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04701-x · Cited by 10
A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
Freeman, K. G., Wetzel, K. S., Zhang, Y., Zack, K. M., Jacobs‐Sera, D., Walters, S., Barbeau, D. J., McElroy, A. K., Williams, J. V., & Hatfull, G. F. (2021) · Microorganisms · doi:10.3390/microorganisms9122414 · Cited by 11
“Vaccines developed by Moderna [24,25] and Pfizer [26] use mRNAs coding for the S protein, although with mutations that promote expression of the pre-fusion S protein conformation.”
BackgroundLoutradis, C., Pitoulias, A. G., Pagkopoulou, E., & Pitoulias, G. A. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-03059-3 · Cited by 13
COVID-19 Vaccine Hesitancy in Australian Patients with Solid Organ Cancers
Bain, N. T., Nguyen, M., Grech, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10091373 · Cited by 10
“COVID-19 vaccines have demonstrated efficacy in reducing infection, serious illness and death, and evidence is growing for real world effectiveness of community-wide vaccination programs (4–7).”
Bajči, M., Lendak, D. F., Ristić, M., Drljača, M., Brkic, S. V., Turkulov, V., & Petrović, V. (2022) · Vaccines · doi:10.3390/vaccines10111818 · Cited by 11
Bettini, E., Chudnovskiy, A., Protti, G., Nakandakari-Higa, S., Ceglia, S., Castaño, D., Chiu, J. E., Muramatsu, H., Mdluli, T., Ábrahám, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.17.594726 · Cited by 10
Zhang, M., Wang, Y., Zhang, T., Zhou, J., Deng, Y., Wang, L., & Du, Y. (2023) · Global Health & Medicine · doi:10.35772/ghm.2022.01063 · Cited by 11
Ocular manifestations of COVID-19 in pediatric patients
Ichhpujani, P., Singh, R. B., Dhillon, H. K., et al. (2023) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414221149916 · Cited by 10
Larkin, A., Waitzkin, H. B., Fassler, E. A., & Nayar, K. R. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063525 · Cited by 10
Eslami, S. M., & Lü, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.035 · Cited by 10
Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency
Milota, T., Smetanová, J., Skotnicová, A., Rataj, M., Lašťovička, J., Zelená, H., Paračková, Z., Fejtková, M., Kanderová, V., Froňková, E., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.10.046 · Cited by 10
Zhou, Y., Li, G., Zhao, T., Du, J., Zhang, W.-Q., Xie, M.-Z., Chen, L.-Y., Zeng, J., Wang, C., Liu, B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28256 · Cited by 9
Galiero, R., Simeon, V., Loffredo, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206121 · Cited by 10
Nakao, H., Koseki, T., Kato, K., Yamada, S., Tsuboi, N., Takahashi, K., & Mizuno, T. (2023) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2023.11453 · Cited by 10
“First, a high incidence of systemic AEs has been reported for the COVID-19 mRNA vaccine, and the incidence of AEs is higher with the second dose than that with the first dose [26, 27]; however, in this study, it was unclear whether the cases had an onset after the first or the second dose of the vaccine.”
ResultBobst, C. E., Sperry, J. B., Friese, O. V., & Kaltashov, I. A. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.1c00091 · Cited by 11
Vaccination of Pregnant Women Against COVID-19
Abu-Raya, B. (2021) · NeoReviews · doi:10.1542/neo.22-9-e570 · Cited by 14
FACME multidisciplinary working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2021.05.001 · Cited by 14
Wood, M. K., Gray, J., Raj, A., et al. (2021) · British and Irish Orthoptic Journal · doi:10.22599/bioj.164 · Cited by 10
Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination
Aalberg, J. J., Collins, T. P., & Dobrow, E. M. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.05.031 · Cited by 10
“html [5] Polack FP , Thomas SJ , Kitchin N , Absalon J , Gurtman A , Lockhart S , et al.”
Cascallar, M., Hurtado, P., Lores, S., Pensado‐López, A., Quelle‐Regaldie, A., Sanchez, L. E., Piñeiro, R., & de la Fuente, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1007018 · Cited by 11
“Additionally, in 2021, mRNA-based vaccines against Covid-19 reached the market (Corbett et al., 2020; Polack et al., 2020), opening a new era for the engineering and application of gene therapy.”
BackgroundMcAndrew, T., Cambeiro, J., & Besiroglu, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.054 · Cited by 13
Trends and Correlates of Breakthrough Infections With SARS-CoV-2
Yamal, J., Appana, S. N., Wang, M., León‐Novelo, L., Bakota, E. V., Ye, Y., Sharma, S. V., Morrison, A. C., Marko, D., Linder, S. H., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.856532 · Cited by 10
“After vaccine series completed NA NA 6 (3, 9) 133 (101, 164)”
BackgroundWillingness to Vaccinate against COVID-19 Declines in Australia, Except in Lockdown Areas
To, Q. G., Stanton, R., Khalesi, S., Williams, S. L., Alley, S., Thwaite, T. L., Fenning, A. S., & Vandelanotte, C. (2021) · Vaccines · doi:10.3390/vaccines9050479 · Cited by 11
“, Pfizer with an efficacy of 95% [9] and AstraZeneca with an efficacy of”
BackgroundChen, P., Behre, G., Hebert, C., Kumar, P. N., Macpherson, L. F., Graham-Clarke, P., de la Torre, I., Nichols, R., Hufford, M. M., Patel, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac172 · Cited by 12
Lelis, F., Byk, L. A., Pustylnikov, S., Nguyen, V., Nguyen, B. T., Nitz, M., Tarte, P., Tungare, K., Li, J., Manna, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46233-6 · Cited by 12
Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine
Qin, J., Jeon, J. H., Xu, J., Langston, L. K., Marasini, R., Mou, S., Montoya, B., Melo‐Silva, C. R., Jeon, H. J., Zhu, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126392 · Cited by 12
“This strategy is effective with RNA vaccines showing up to 95% efficacy (10, 12).”
BackgroundSARS‐CoV‐2 vaccination in patients with inflammatory bowel disease
Prentice, R., Rentsch, C. A., Al‐Ani, A., Zhang, E., Johnson, D. F., Halliday, J., Bryant, R. V., Begun, J., Ward, M. G., Lewindon, P. J., et al. (2021) · GastroHep · doi:10.1002/ygh2.473 · Cited by 10
Ang, S., Huang, Y., & Chang, C. (2023) · Medicina · doi:10.3390/medicina59030627 · Cited by 10
Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury
Akkız, H. (2023) · Viruses · doi:10.3390/v15061287 · Cited by 11
Naiditch, H., Betts, M. R., Larman, H. B., Levi, M., & Rosenberg, A. Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1376654 · Cited by 10
Tene, L., Karasik, A., Chodick, G., Pereira, D. I. A., Schou, H., Waechter, S., Göhring, U., & Drakesmith, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285606 · Cited by 9
Laotee, S., Duangkaew, M., Jivapetthai, A., Tharakhet, K., Kaewpang, P., Prompetchara, E., Phumiamorn, S., Sapsutthipas, S., Trisiriwanich, S., Somsaard, T., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288486 · Cited by 10
Emerging Immunotherapies in Lung Cancer: The Latest Advances and the Future of mRNA Vaccines
Ramos, R., & Vale, N. (2025) · Vaccines · doi:10.3390/vaccines13050476 · Cited by 11
“Despite all the advantages of the acid nucleic vaccines described, RNA-based vaccines have arisen as an interesting alternative to DNA vaccines for cancer treatment, especially vaccines using messenger RNA (mRNA) [39,44], and its popularity has risen with COVID-19 vaccines [39,54–56].”
Franzese, M., Coppola, L., Silva, R., Santini, S. A., Cinquanta, L., Ottomano, C., Salvatore, M., & Incoronato, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947187 · Cited by 11
“With a 95% efficiency rate achieved with two doses administered 21 days apart and with few side effects (1, 2), the vaccine was quickly approved.”
BackgroundStinca, S., Barnes, T. W., Peter, V., Meyers, W., Schulte-Pelkum, J., Filchtinski, D., Steller, L., Hauser, T., Manni, S., Gardiner, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259731 · Cited by 10
“Firstly, the success of several COVID-19 vaccines in preventing COVID-19 infection [13], coupled with the substantially elevated anti-SARS-CoV-2 antibody levels of vaccinated individuals [4, 7, 8], PLOS ONE Anti-SARS-CoV-2 IgG concentration in intravenous immunoglobulin product batches”
BackgroundCommon Side Effects of Pfizer COVID-19 Vaccine: An Experience From Pakistan
Haider, S. M. S., Alvi, S. A., Khan, H. A., Majeed, R., Syed, T., Anwar, A., & Hashmi, A. A. (2023) · Cureus · doi:10.7759/cureus.40878 · Cited by 10
Dunn, D. T., Stirrup, O., McCormack, S., & Glidden, D. V. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-01970-0 · Cited by 12
“Hypothetical COVID‐19 vaccine trial The first licensed COVID-19 vaccine, BNT162b2 (BioNTech/Pfizer), was found to reduce the incidence of COVID-19 by approximately 95% [7].”
BackgroundVaccination efficacy in patients with chronic lymphocytic leukemia
Wang, K. Y., Shah, P., Skavla, B., Fayyaz, F., Chi, J., & Rhodes, J. M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2133538 · Cited by 11
Projecting the Pandemic Trajectory through Modeling the Transmission Dynamics of COVID-19
Vakil, V., & Trappe, W. K. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084541 · Cited by 11
“These levels of immunity are achieved 2 weeks after the second dose of the Moderna and Pfizer vaccines, or 2-weeks after a single dose of the Janssen vaccine.”
BackgroundInfluentialLin, Y., Lin, M., Chuang, Y.-S., Liu, L. T.-C., Kuo, T., Chen, C., Ganesan, S., Fattom, A., Bitko, V., & Lien, C.-E. (2022) · Scientific Reports · doi:10.1038/s41598-022-15238-y · Cited by 12
Lima, G. G., Portilho, A. I., & Gaspari, E. D. (2022) · Pathogens and Disease · doi:10.1093/femspd/ftac038 · Cited by 10
“Regarding SARS-CoV-2, not only animal studies observed that (Guebre-Xabier et al. 2020, Jangra et al. 2021, Santana-Mederos et al. 2022, Scaria et al. 2022), but also clinical trials from vaccines in use (Folegatti et al. 2020, Polack et al. 2020, Zhang et al. 2021).”
BackgroundMonoclonal antibody levels and protection from COVID-19
(2022) · doi:10.1101/2022.11.22.22282199 · Cited by 10
Alhossan, A., Alsaran, A. K., Almahmudi, A. H., Aljohani, Z. S., Albishi, M. R., & Almutairi, A. K. (2022) · Vaccines · doi:10.3390/vaccines10122089 · Cited by 11
Autoimmune‐Like Hepatitis Related to SARS ‐ CoV ‐2 Vaccination: Towards a Clearer Definition
Efe, C., Uzun, S., Matter, M. S., & Beretta‐Piccoli, B. T. (2024) · Liver International · doi:10.1111/liv.16209 · Cited by 11
“Acute liver injury is a very rare side effect of SARS- CoV-2 vaccines and therefore has not been reported in clinical trials (phase II/III), which included a limited number of subjects [19, 20].”
Torres, T. S., Luz, P. M., Coelho, L. E., Jalil, C. M., Falco, G. G., Sousa, L. P., Jalil, E. M., Bezerra, D. R. B., Cardoso, S. W., Hoagland, B., et al. (2021) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2021.101600 · Cited by 13
COVID‐19 vaccine associated cervical lymphadenopathy: a case series
Heaven, C. L., Barber, L., Ahmadi, O., et al. (2022) · ANZ Journal of Surgery · doi:10.1111/ans.17808 · Cited by 10
Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population
Weinberger, B. (2021) · Vaccines · doi:10.3390/vaccines9121435 · Cited by 11
“Statistical evaluation of efficacy was therefore not possible for this age group [31,42].”
BackgroundPatel, R. S., & Agrawal, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952229 · Cited by 10
Denaro, M. F., Ferro, E., Barrano, G., Meli, S., Busacca, M., Corallo, D., Capici, A., Zisa, A., Cucuzza, L., Gradante, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054742 · Cited by 10
“months after the second dose [3], whereas the efficacy decreases to 84% from four to six months after the second dose [4].”
BackgroundA review of COVID vaccines: success against a moving target
Chong, S. H., Burn, L. A., Cheng, M. T. K., Warr, I. S., & Kenyon, J. C. (2022) · British Medical Bulletin · doi:10.1093/bmb/ldac025 · Cited by 9
Tolan, N. V., Sherman, A. C., Zhou, G., Smith, K. N., Desjardins, M., Melanson, S. E. F., Kanjilal, S., Moheed, S., Kupelian, J. A., Kaufman, R. M., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00211-22 · Cited by 10
“Both vaccines are administered as two-dose series, 21 (BNT162b2) or 28 days (mRNA-1273) apart, demonstrated 94% to 95% efficacy in clinical trials (7, 8), and have since received EUA for a single booster $ 6 months after the primary series (9).”
BackgroundArlt, F. A., Breuer, A., Trampenau, E., Boesl, F., Kirchner, M., Mertins, P., Sánchez-Sendín, E., Nasouti, M., Mayrhofer, M., Blüthner, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1404800 · Cited by 11
Applications and challenges of biomaterial mediated mRNA delivery
Fang, H., & Chen, Q. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00093 · Cited by 13
Alishetty, S., Carrasco, M. J., Alameh, M., Paige, M. A., Said, H., Wright, L., Narayanan, A., Alem, F., Hernandez, K. R., Gillevet, P. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-798453/v1 · Cited by 10
“2 g) and tert-Butyl acrylate(46) (4) (3.”
Jeong, Y. D., Lee, K., Lee, S., Park, J., Kim, H. J., Lee, J., Kang, J., Jacob, L., Smith, L., Rahmati, M., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29682 · Cited by 11
Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
Ai, Y., Wang, H., Zheng, Q., Li, S., Liu, J., Huang, J. W., Tang, J., & Meng, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174184 · Cited by 14
“However, there is limited information on the safety and efficacy of the vaccine in patients with cancer because vulnerable populations, including immunocompromised patients, are not involved in research development and clinical trials of the vaccine (90).”
BackgroundDiagnosis of COVID-19 in symptomatic patients: An updated review
Zahan, M. N., Habibi, H., Pencil, A., Abdul‐Ghafar, J., Ahmadi, S. A., Juyena, N. S., Rahman, M. T., & Parvej, M. S. (2021) · Vacunas (English Edition) · doi:10.1016/j.vacun.2021.06.002 · Cited by 11
Lau, O., & Vadlamudi, N. K. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.003 · Cited by 10
“approved for emergency use of their newly developed messenger RNA vaccines and are now in circulation; publications on both vaccines reported high efficacy.(13,14) A total of 3 systematic and meta-analysis studies have been previously conducted by Yuan et al,(15) Pormohammad et al,(16) and Kai et al(17) on COVID-19 va…”
Application of Bayesian Methods to Help Interpret the VANCO Trial Results
O’Hara, N. N., Castillo, R. C., Carlini, A. R., Joshi, M. G., Murray, C. K., Allen, L., Huang, Y., Gary, J. L., Bosse, M. J., Obremskey, W. T., et al. (2022) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000002458 · Cited by 11
Vlach, M., Coppens-Exandier, H., Jamin, A., Berchel, M., Scaviner, J., Chesné, C., Montier, T., Jaffrès, P., Corlu, A., & Loyer, P. (2022) · Cells · doi:10.3390/cells11233904 · Cited by 10
Dhanasekaran, P., Karasu, B. T., & Mak, A. (2024) · Rheumatology International · doi:10.1007/s00296-024-05734-x · Cited by 11
“There is growing evidence [19–21] that COVID-19 mRNA vaccines are safe and effective for use in patients with AIIRD despite initial trials that have excluded these patients [12, 22].”
Should the two‐trial paradigm still be the gold standard in drug assessment?
Zhan, S. J., Kunz, C. U., & Stallard, N. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2262 · Cited by 9
Placido, P. D., Pietroluongo, E., Angelis, C. D., Tafuro, M., Barraco, C., Giannatiempo, R., Buonaiuto, R., Schettini, F., Iervolino, A., Vozzella, E. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.951026 · Cited by 10
“Since then, more than 540 million (544,612,990) cases of COVID-19 have been confirmed up to June 2022, with 6 million (6,330,811) deaths (3).”
BackgroundAdvancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies
Yaremenko, A. V., Печникова, Н. А., & Chuang, L. I. U. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c03826 · Cited by 14
Application of estimand framework in ICH E9 (R1) to vaccine trials
Fu, R., Li, H., Wang, X., Shou, Q., & Wang, W. W. B. (2023) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2023.2197040 · Cited by 11
Tuells, J., Parra-Grande, M., Santos-Calle, F. J., Montagud, A. C., Egoavil, C. M., García-Rivera, C., Caballero, P., Bravo, E. M. G., Rodríguez, J. C., & Sánchez, J. A. H. (2022) · Vaccines · doi:10.3390/vaccines10040510 · Cited by 12
Parry, H., Bruton, R. K., Ayodele, R., Sylla, P., McIlroy, G., Logan, N. A., Scott, S., Nicol, S., Verma, K., Stephens, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100739 · Cited by 14
Zayou, L., Prakash, S., Vahed, H., Dhanushkodi, N. R., Quadiri, A., Belmouden, A., Lemkhente, Z., Chentoufi, A. A., Gil, D., Ulmer, J. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1503954 · Cited by 14
Behzadi, S., & Mahmoudi, M. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.02.012 · Cited by 11
Liozon, É., Filloux, M., Parreau, S., Gondran, G., Bézanahary, H., Ly, K. H., & Fauchais, A. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247484 · Cited by 10
Leong, D. P., Zhang, A., Breznik, J. A., Clare, R., Huynh, A., Mushtaha, M., Rangarajan, S., Stacey, H. D., Kim, P. Y., Loeb, M. B., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281673 · Cited by 10
“The BNT162b2 mRNA COVID-19 vaccine, has been authorized for a short dosing interval of 3 weeks, as this was the only dosing schedule examined in the vaccine approval trials [1, 2].”
BackgroundMarkewitz, R. D. H., Juhl, D., Pauli, D., Görg, S., Junker, R., Rupp, J., Engel, S., Steinhagen, K., Herbst, V., Zapf, D., et al. (2022) · Vaccines · doi:10.3390/vaccines10050649 · Cited by 10
“Since the end of 2020, several vaccines, using different modes of action on the molecular level, have been approved and administered in most parts of the world, among them the adenoviral vector vaccine ChAdOx1 nCoV-19 (ChAdOx, AstraZeneca, Cambridge, UK) [2], and the two mRNA vaccines BNT162b2 (BNT, BioNTech/Pfizer, M…”
BackgroundPanahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10
Alcolea, P. J., Larraga, J., Rodríguez-Martín, D., Alonso, A., Loayza, F. J., Rojas, J. M., Ruiz-García, S., Louloudes-Lázaro, A., Carlón, A. B., Sánchez‐Cordón, P. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023255 · Cited by 11
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.